Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Improving Immunotherapy For Breast Cancer
Disease Discoveries

Improving Immunotherapy For Breast Cancer

By Will DossOct 15, 2020
Share
Facebook Twitter Email
Yong Wan, PhD, professor of Obstetrics and Gynecology in the Division of Reproductive Science in Medicine, professor of Pharmacology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was senior author of the study published in Cancer Discovery.

Treatment-resistant breast cancer could be made vulnerable to immunotherapy by flipping a metabolic “switch,” according to a Northwestern Medicine study published in Cancer Discovery.

This strategy could represent a breakthrough in treating tumors that otherwise don’t respond to cancer immunotherapy, according to Yong Wan, PhD, professor of Obstetrics and Gynecology in the Division of Reproductive Science in Medicine and senior author of the study.

“This model could be very attractive for treating triple-negative breast cancer,” said Wan, who is also a professor of Pharmacology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Xinxin Song, MD, PhD, and Zhuan Zhou, PhD, were co-first authors of the paper.

Immunotherapy is a form of cancer treatment that inhibits immune regulators that normally keep the body’s T-cells in check. In healthy patients, these regulators prevent the immune system from becoming overactive and attacking healthy cells. For patients with cancer, triggering this highly-charged immune response can actually help, unleashing those T-cells to attack cancer.

However, some cancers locally inhibit immune activity in order to grow, rendering immunotherapy useless, according to Wan.

“These ‘immune-cold’ tumors have no response to immunotherapy,” Wan said. “Immunotherapy is important, but we’ve hit a bottleneck.”

In the current study, Wan and his collaborators analyzed protein levels in 81 patients with triple-negative breast cancer, a form of breast cancer that does not respond to most therapies. They found that high levels of an immune-dampening protein called B7-H4 correlated with worsening disease progression and resistance to immunotherapy.

“This protein is very involved in ‘don’t eat me’ immune signaling,” Wan said. “This behavior suggests it could be a good target.”

Searching for ways to modulate the protein, the investigators explored its regulation, finding a push and pull between two different metabolic compounds. One form of regulation, ubiquitination, degrades the protein, while another form, glycosylation, stabilizes and protects the protein.

“We want to degrade the protein, so inhibition of glycosylation might have a clinical use,” Wan said.

Accordingly, the investigators tested a glycosylation inhibitor in mouse models of triple-negative breast cancer, combining it with immunotherapy to simulate how it might be used in patients. They found that it effectively turned this form of cancer into an “immune-hot” tumor, and the efficacy of the immunotherapy soared compared to control models who did not receive the inhibitor.

“It had a fantastic mechanistic effect,” Wan said.

In the future, Wan plans to develop screens that use B7-H4 as a biomarker of immunotherapy resistance in cancer. In addition, while Wan said he hopes to develop a more specific inhibitor, this two-part process could nonetheless make immunotherapy a real treatment option both for triple-negative breast cancer and for other cancers that rely on B7-H4.

“We’ve also seen it in ovarian cancer and lung cancer, so this could be a great way to turn these immune-cold tumors into immune-hot ones,” Wan said.

The Wan laboratory is supported by the Northwestern University Zell scholar fund and the National Institutes of Health grants R01CA202963, R01CA202948 and R01CA250110.

Cancer Immunology Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.